Healthcare Industry News: HSMN NewsFeed
News Release - October 4, 2018
HCG is First in India to Treat Cancer Patients Using the Accuray Radixact(R) SystemAdoption of Innovative Radiation Therapy Technology Reinforces South Asian Cancer Center's Position as Pioneer in Patient Care
SUNNYVALE, Calif., Oct. 4, 2018 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today that the clinical team at Healthcare Global Enterprises (HCG) EKO, Kolkata, has treated the first patient in India using the Radixact® System. HCG EKO is part of Healthcare Global Enterprises Ltd HCG, India's largest provider of cancer care. The Radixact System marks a major step forward in treatment precision, speed, efficiency and ease of use with the potential to provide significant clinical benefits to cancer patients in India.
An early adopter of leading-edge technology, HCG was also the first in India to introduce the TomoH™ System, a fully integrated 3D conformal and image-guided intensity-modulated radiation therapy (IG-IMRT) system, and the CyberKnife® Robotic Radiosurgery System, technology designed to deliver stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT).
Dr. BS Ajaikumar, Chairman & CEO, HCG Enterprises Ltd said, "Being at the forefront of the fight against cancer, HCG strives to offer precision treatment to cancer patients, reinforcing the ideology – the right way, the first time. The practice of adopting cutting-edge technologies like the Radixact System, along with our clinical expertise, has enabled us to move one step closer towards precise and personalized care, therefore improving the quality of life of cancer patients."
According to data from the International Agency for Research on Cancer's GLOBOCAN initiativei, the number of new cases of cancer diagnosed in India will grow from approximately 1 million per year in 2012 to more than 1.5 million by 2030. Based on 2012 estimates, breast, cervical, head and neck, and lung cancers account for more than 50 percent of new cases diagnosedi. The Radixact System's unique ring gantry architecture and efficient daily low-dose fan beam 3DCT image guidance make it an optimal solution for treating these tumors, as well as the complete range of radiation therapy indications.
Watch the Radixact System in action at this link: https://youtu.be/vMTRm3qObeU
"For years, HCG and Accuray have partnered to bring advanced cancer care to India with the goal of improving the lives of those diagnosed with this disease," said Lionel Hadjadjeba, M.D., Senior Vice President and Chief Commercial Officer at Accuray. "HCG's selection of the Radixact System reflects growing market acceptance of this next-generation TomoTherapy® platform as a true workhorse for the treatment of virtually all cancer cases, as well as continued momentum for our products in key markets around the world. We congratulate HCG on this milestone and look forward to continuing our collaboration to bring clinical and technological innovation to India."
Personalized, precise treatments tailored to each patient's needs
- The Radixact System offers clinicians the flexibility to deliver treatment from clinician-specified beam angles with TomoDirect™ mode, or by continuous delivery of radiation from 360 degrees around the patient using TomoHelical™ mode, resulting in highly accurate, individualized dose distributions that precisely conform to the shape of the patient's tumor
- A built-in CT scanner performs daily imaging before each treatment session. The daily imaging capability makes it possible for clinicians to identify and correct for any variations in patient positioning, changes in the tumor or in other factors, such as weight gain or loss, to ensure the continued precise and safe delivery of the radiation dose to the target area
- Fully-integrated and easy to use, an adaptive treatment planning solution called PreciseART™ Adaptive Radiation Therapy Software enables the clinical team to adjust therapy to changes in patient anatomy during the course of treatment, including both changes in the tumor size, shape, and location as well as changes in surrounding healthy tissue
- The PreciseRTX™ Retreatment Option makes it easier for clinicians to plan and deliver precise doses of radiation in those cases where, unfortunately, cancer has recurred and retreatment with radiation is necessary
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, market acceptance of Accuray's products, Accuray's ability to continue momentum for its products in key markets, and Accuray's ability to continue to penetrate the global radiation therapy market. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, the company's ability to effectively manage its growth, the company's ability to maintain or increase its gross margins on product sales and services, the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands, and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 24, 2018, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
i Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. 2013. http://globocan.iarc.fr; accessed on 2/20/2018
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsPhase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer
Accuray and China Isotope and Radiation Corporation Enter Joint Venture Contract to Manufacture and Sell Radiation Oncology Systems in China
Accuray CyberKnife(R) System Treatment Delivery Times Up to 50 Percent Faster With Software Upgrade